Societe Generale Cross Asset Research reinforces its pharma sector coverage
Societe Generale Cross Asset Research announces the appointment Florent Cespedes as Senior Equity Analyst, as of 5 January 2015. Based in Paris, he will be responsible for the large and mid caps companies of the European pharmaceutical sector. In this new role, he reports to Fabrice Theveneau, Head of Equity and Credit Research.
Societe Generale Cross Asset Research announces the appointment Florent Cespedes as Senior Equity Analyst, as of 5 January 2015. Based in Paris, he will be responsible for the large and mid caps companies of the European pharmaceutical sector. In this new role, he reports to Fabrice Theveneau, Head of Equity and Credit Research.
Before joining the Bank, Florent Cespedes was an Equity Analyst for Exane covering the pharmaceutical sector since 2006.
In addition, Justin Smith who is currently in charge of the medical technology sector, will also cover large pharmaceutical companies with Florent. The coverage of the biotechnology sector will continue to be under the responsibility of Delphine Le Louet.
Notes to editors
Biography
Florent Cespedes was previously an Equity Analyst for Exane covering the pharmaceutical sector from 2006 to 2015. Prior to that, he was Head of the European Pharma team for Natixis from 2003 to 2006. He has also worked for Fortis as Head of the European Pharma team from 2000 to 2003. Florent Cespedes is a pharmaceutical Doctor with an industry specialty from the University of Montpellier and holds a Masters in Finance from ESCP.
日本のエネルギー・トランジションに向けて「東」と「西」を結ぶ
昨年ソシエテ・ジェネラルがグローバルロードショーの一環として開催した「ポジティブ・インパクト・デー」の東京会場では、日本の脱炭素化政策と国際的なパートナーとしての役割について、最新の動向を踏まえた活発な議論がなされました。
2024年第4四半期および2024年通期決算
パリ、2025年2月6日